Prescriber Opinions on Biosimilars in Immunology, 2021 Report – Focus on US, France, Germany, Italy, Spain, UK, Japan & India – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Advice of prescribers on biosimilars in immunology” report has been added to from ResearchAndMarkets.com offer.
This report covers 7MM (USA, France, Germany, Italy, Spain, UK and Japan) and India and provides key research findings from specialists interviewed for this report including Dermatologists, Gastroenterologists and rheumatologists who treat the most common autoimmune diseases. (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, Crohn’s disease and plaque psoriasis) on the use of biosimilars for the treatment of these conditions.
A high proportion of all physicians surveyed reported prescribing biosimilars to their immunology patients in 2019 as biosimilars are increasingly used in cost-conscious healthcare systems in Europe. The main reason why not all patients received a biosimilar was due to patients’ doubts about the effectiveness of the biosimilar.
As such, the main factor likely to encourage an increase in biosimilar prescribing is the availability of actual data on the biosimilar in each country where it is used.
Topics covered include:
Overview and perception of biosimilar prescriptions
Incentives or disincentives for prescribing biosimilars
Price regulation and discounts
Factors influencing the choice of brands of prescribed biosimilars
Future directions for the use of biosimilars
Reasons to buy
Develop business strategies by understanding the trends shaping and driving the Indian 7MM and biosimilars market.
Generate revenue by understanding key trends that are likely to impact India’s 7MM and biosimilars market.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Organize your sales and marketing efforts by identifying the categories and market segments that present the maximum opportunities for consolidations, investments and strategic partnerships.
Main topics covered:
1 Table of Contents
2 main findings
3 Overview and perception of biosimilar prescriptions
3.1 Overview of biosimilar prescribing
3.2 Use of biosimilars – Infliximab versus Remicade
3.3 Use of biosimilars – Etanercept versus Enbrel
3.4 Use of biosimilars – Adalimumab versus Humira
3.5 Use of biosimilars – Reasons for not prescribing biosimilars to all patients
3.6 Use of biosimilars – Factors that may encourage increased use of biosimilars
3.7 Biosimilar prescriptions in treatment-naïve patients versus treatment-experienced patients
3.8 Perception of whether biosimilars are inexpensive, save money and improve patient access
4 Incentives and Disincentives for Prescribing Biosimilars
4.1 Incentives or disincentives for physicians to prescribe biosimilars
5 Price regulation and discounts
5.1 Price regulation of new biologics and biosimilars
5.2 Biosimilar price regulation on 8MM
5.3 Discounts provided by biosimilars compared to the price of the originator product
5.4 Discounts needed for physicians to prescribe biosimilars to >50% of patients
6 Reimbursement of biosimilars
6.1 Reimbursement of biosimilars for all indications versus certain indications
7 factors influencing the choice of brands of prescribed biosimilars
7.1 Factors Influencing Decisions on Prescribed Biosimilar Brands – 8MM
7.2 Factors influencing the choice of brands of prescribed biosimilars – US
7.3 Factors Influencing the Choice of Prescribed Biosimilar Brands – Preferred Manufacturers
8 future directions
8.1 Future directions – Initiatives that may encourage the use of biosimilars
8.2 Future directions – Predictions of future use of biosimilars over the next five years
For more information on this report, visit https://www.researchandmarkets.com/r/pzfagl